Advertisement

Modeling The Costs and Effects of Maintenance Treatment for Opiate Addiction

  • Gregory S. Zaric
Part of the International Series in Operations Research & Management Science book series (ISOR, volume 70)

Summary

In this chapter we discuss recent operations research advances in modeling drug treatment programs for injection drug users, in particular maintenance treatment programs for opioid addicts. We focus on four main questions for which operations research techniques have proven beneficial: How effective are opioid maintenance programs? Do the benefits of methadone maintenance treatment justify its costs? Are alternative forms of maintenance treatment cost effective? If opioid maintenance treatment programs are expanded, how many new treatment slots are needed? We discuss a number of methodological issues and highlight directions for future research.

Key words

HIV Methadone Cost-effectiveness analysis Cost-benefit analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Spencer, B.D. (1989). On the accuracy of estimates of numbers of intravenous drug users. In AIDS: Sexual Behavior and Intravenous Drug Use, C.F. Turner, H.G. Miller, and L.E. Moses, Eds., National Academy Press, Washington, DC.Google Scholar
  2. [2]
    Hahn, R.A., I.M. Onorato, T.S. Jones, and J. Dougherty (1989). Prevalence of HIV infection among intravenous drug users in the United States. Journal of the American Medical Association, 261, 2677–2684.CrossRefPubMedGoogle Scholar
  3. [3]
    Nicolosi, A., et al. (1992). Incidence and prevalence trends of HIV infection in intravenous drug users attending treatment centers in Milan and northern Italy, 1986–1990. Journal of Acquired Immune Deficiency Syndromes, 5, 365–373.PubMedMathSciNetGoogle Scholar
  4. [4]
    Centers for Disease Control and Prevention (2001). HIV/AIDS Surveillance Report. Morbidity and Mortality Weekly Report, 13.Google Scholar
  5. [5]
    Hadeler, K.P. and C. Castillo-Chavez (1995). A core group model for disease transmission. Mathematical Biosciences, 128, 41–55.CrossRefPubMedGoogle Scholar
  6. [6]
    Haverkos, H.W. and W.R. Lange (1990). Serious infections other than human immunodeficiency virus among intravenous drug abusers. Journal of Infectious Diseases, 161, 894–902.PubMedGoogle Scholar
  7. [7]
    Watterson, O., D.D. Simpson, and S.B. Sells (1975). Death rates and causes of death among opioid addicts in community drug treatment programs during 1970–1973. American Journal of Drug and Alcohol Abuse, 2, 99–111.PubMedCrossRefGoogle Scholar
  8. [8]
    Gronbladh, L., L.S. Ohlund, and L.M. Gunne (1990). Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatrica Scandinavica, 82, 223–227.PubMedCrossRefGoogle Scholar
  9. [9]
    Gerstein, D.R., et al. (1994). Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA), California Department of Alcohol and Drug Programs, Sacramento, CA.Google Scholar
  10. [10]
    U.S. Department of Commerce (1997). Statistical Abstract of the United States, U.S. Department of Commerce, Washington, DC.Google Scholar
  11. [11]
    Bell, J. and D. Zador (2000). A risk-benefit analysis of methadone maintenance treatment. Drug Safety, 22, 179–190.CrossRefPubMedGoogle Scholar
  12. [12]
    Ralston, G.E. and P. Wilson (1996). Methadone programmes: The costs and benefits to society and the individual. Pharmacoeconomics, 10, 321–326.PubMedCrossRefGoogle Scholar
  13. [13]
    Dole, V.P. and M.E. Nyswander (1976). Methadone maintenance treatment. A ten-year perspective. Journal of the American Medical Association, 235, 2117–2119.CrossRefPubMedGoogle Scholar
  14. [14]
    Marsch, L.A. (1998). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: ameta-analysis. Addiction, 93, 515–532.CrossRefPubMedGoogle Scholar
  15. [15]
    Kwiatkowski, C.F. and R.E. Booth (2001). Methadone maintenance as HIV risk reduction with street-recruited injecting drug users. Journal of Acquired Immune Deficiency Syndromes, 26, 483–489.PubMedGoogle Scholar
  16. [16]
    Sambamoorthi, U., L.A. Warner, S. Crystal, and J. Walkup (2000). Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug and Alcohol Dependence, 60, 77–89.CrossRefPubMedGoogle Scholar
  17. [17]
    Desmond, D.P. and J.F. Maddux (2000). Deaths among heroin users in an out of methadone treatment. Journal of Maintenance in the Addictions, 1, 45–61.CrossRefGoogle Scholar
  18. [18]
    Rettig, R.A. and A. Yarmolinsky, Eds. (1995). Federal Regulation of Methadone Treatment. National Academy Press, Washington, DC.Google Scholar
  19. [19]
    U.S. Drug Enforcement Administration (2002). DEA Briefs: Background, Drug Policy, Drug Scheduling, http://www.usdoj.gov/dea/pubs/scheduling.html, Accessed August 12, 2002.
  20. [20]
    Stone, E. (2002). Family torn by addiction. Without methadone clinic, son is forced out of state. Burlington Free Press, Burlington, VT, January 20.Google Scholar
  21. [21]
    Bradley, C.J., M.T. French, and J.V. Rachal (1994). Financing and cost of standard and enhanced methadone treatment. Journal of Substance Abuse Treatment, 11, 433–442.CrossRefPubMedGoogle Scholar
  22. [22]
    Barnett, P.G. and J.H. Rodgers (1998). The Cost of Substance Abuse Treatment: A Multivariate Cost Function Using the NDATUS, VA Health Care System, Palo Alto, CA.Google Scholar
  23. [23]
    Barnett, P.G. and S.S. Hui (2000). The cost-effectiveness of methadone maintenance. Mount Sinai Journal of Medicine, 67, 365–374.PubMedGoogle Scholar
  24. [24]
    Riza, M. (1998). Close to Home Online-Policy: The Politics of Methadone, http://www.pbs.org/wnet/closetohome/policy/html/methadone.html, Accessed August 12, 2002.
  25. [25]
    Mathias, R. (1997). NIH panel calls for expanded methadone treatment for heroin addiction. NIDA Notes, 12.Google Scholar
  26. [26]
    Lambert, E.Y., H.K. Cesari, R.H. Needle, and J.B. Stein (2002). Principles of HIV Prevention in Drug-Using Populations: A Research-Based Guide, National Institute on Drug Abuse, Washington, DC.Google Scholar
  27. [27]
    U.S. Senate (1999). Senator John McCain-Press Releases, http://www.senate.gov/~mccain/methhero.htm, Accessed August 12, 2002.
  28. [28]
    Swarns, R.L. (1998). Giuliani orders 5 city hospitals to wean addicts off methadone. New York Times, New York, August 15.Google Scholar
  29. [29]
    Rubinowitz, S. (1999). Turnaround Rudy puts $5M in methadone clinics. New York Post, New York, October 6, 4.Google Scholar
  30. [30]
    Lee, M.L. (1992). A Markov model for NIDA data on treatment of opiate dependence. NIDA Research Monographs, 128, 160–169.Google Scholar
  31. [31]
    Weng, T.S. (1992). Toward a dynamic analysis of disease-state transition monitored by clinical laboratory tests. NIDA Research Monographs, 128, 137–157.ADSMathSciNetGoogle Scholar
  32. [32]
    Johnson, R.E. and P.J. Fudala (1992). Background and design of a controlled clinical trial (ARC 090) for the treatment of opioid dependence. NIDA Research Monographs, 128, 14–24.Google Scholar
  33. [33]
    Phelps, C.E. and A.I. Mushlin (1991). On the (near) equivalence of cost-effectiveness and cost-benefit analyses. International Journal of Technology Assessment in Health Care, 7, 12–21.PubMedCrossRefGoogle Scholar
  34. [34]
    Donaldson, C. (1998). The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy? Pharmacoeconomics, 13, 389–396.CrossRefPubMedGoogle Scholar
  35. [35]
    Laska, E.M., M. Meisner, C. Siegel, and A.A. Stinnett (1999). Ratio-based and net benefit-based approaches to health care resource allocation: proofs of optimality and equivalence. Health Economics, 8, 171–174.CrossRefPubMedGoogle Scholar
  36. [36]
    Bala, M.V., G.A. Zarkin, and J.A. Mauskopf (2002). Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses. Value in Health, 5, 338–346.CrossRefPubMedGoogle Scholar
  37. [37]
    Dolan, P. and R. Edlin (2002). Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis? Journal of Health Economics, 21, 827–843.CrossRefPubMedGoogle Scholar
  38. [38]
    Kaplan, R.M. (1995). Utility assessment for estimating quality-adjusted life years. In Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies, F.A. Sloan, Ed., Cambridge University Press, Cambridge, UK.Google Scholar
  39. [39]
    French, M.T., J.A. Mauskopf, J.L. Teague, and E.J. Roland (1996). Estimating the dollar value of health outcomes from drug-abuse interventions. Medical Care, 34, 890–910.CrossRefPubMedGoogle Scholar
  40. [40]
    Hannan, T.H. (1976). The benefits and costs of methadone maintenance. Public Policy, 24, 197–226.Google Scholar
  41. [41]
    French, M.T., H.J. Salome, J.L. Sindelar, and A.T. McLellan (2002). Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI. Health Services Research, 37, 433–455.CrossRefPubMedGoogle Scholar
  42. [42]
    Viscusi, W.K. (1993). The value of risks to life and health. Journal of Economic Literature, 32, 1912–1946.Google Scholar
  43. [43]
    French, M.T., et al. (2000). Benefit-cost analysis of residential and outpatient addiction treatment in the State of Washington. Evaluation Review, 24, 609–634.ADSPubMedCrossRefGoogle Scholar
  44. [44]
    McLellan, A.T., et al. (1992). The fifth edition of the Addiction Severity Index. Journal of Substance Abuse Treatment, 9, 199–213.CrossRefPubMedGoogle Scholar
  45. [45]
    Gold, M.R., J.E. Siegel, L.B. Russell, and M.C. Weinstein (1996). Cost-Effectiveness in Health and Medicine. Oxford University Press, New York.Google Scholar
  46. [46]
    Barnett, P.G. (1999). The cost-effectiveness of methadone maintenance as a health care intervention. Addiction, 94, 479–488.CrossRefPubMedGoogle Scholar
  47. [47]
    Kahn, J.G., et al. (1992). Updated estimates of the impact and cost of HIV prevention in injection drug users. Report prepared for Centers for Disease Control and Prevention. University of California, San Francisco, CA.Google Scholar
  48. [48]
    Zaric, G.S., P.G. Barnett, and M.L. Brandeau (2000). HIV transmission and the cost effectiveness of methadone maintenance. American Journal of Public Health, 90, 1100–1111.PubMedCrossRefGoogle Scholar
  49. [49]
    Zaric, G.S., M.L. Brandeau, and P.G. Barnett (2000). Methadone maintenance treatment and HIV prevention: A cost effectiveness analysis. Management Science, 25, 1013–1031.CrossRefGoogle Scholar
  50. [50]
    Booth, R.E. (1995). Gender differences in high-risk sex behaviors among heterosexual drug injectors and crack smokers. American Journal of Drug and Alcohol Abuse, 21, 419–432.PubMedCrossRefGoogle Scholar
  51. [51]
    Battjes, R.J., R.W. Pickens, and Z. Amsel (1991). HIV infection and AIDS risk behaviors among intravenous drug users entering methadone treatment in selected U.S. cities. Journal of Acquired Immune Deficiency Syndromes, 4, 1148–1154.PubMedGoogle Scholar
  52. [52]
    Davis, K.R. and S.C. Weller (1999). The effectiveness of condoms in reducing heterosexual transmission of HIV. Family Planning Perspectives, 31, 272–279.PubMedCrossRefGoogle Scholar
  53. [53]
    Pinkerton, S.D., A.P. Johnson-Masotti, D.R. Holtgrave, and P.G. Farnham (2001). Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS, 15, 917–928.PubMedCrossRefGoogle Scholar
  54. [54]
    Raisch, D.W., C.L. Fye, K.D. Boardman, and M.R. Sather (2002). Opioid dependence treatment, including buprenorphine/naloxone. Annals of Pharmacotherapy, 36, 312–321.PubMedCrossRefGoogle Scholar
  55. [55]
    Lewis, J.L. and D. Walter (1992). Buprenorphine-background to its development as a treatment for opiate dependence. In Buprenorphine: An Alternative Treatment for Opioid Dependence, J.D. Blaine, Ed., U.S. Department of Health and Human Services, Rockville, MD.Google Scholar
  56. [56]
    Barnett, P.G., G.S. Zaric, and M.L. Brandeau (2001). The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction, 96, 1267–1278.PubMedCrossRefGoogle Scholar
  57. [57]
    Barnett, P.G., J.H. Rodgers, and D.A. Bloch (2001). A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction, 96, 683–690.PubMedCrossRefGoogle Scholar
  58. [58]
    Rosenheck, R. and T. Kosten (2001). Buprenorphine for opiate addiction: potential economic impact. Drug and Alcohol Dependence, 63, 253–262.CrossRefPubMedGoogle Scholar
  59. [59]
    French, M.T. (2001). Cost-effectiveness of buprenorphine maintenance versus methadone maintenance: a comment on Barnett et al. (2001). Addiction, 96, 1515–1517.PubMedGoogle Scholar
  60. [60]
    Reuter, P. (2001). Cost-effectiveness estimates for buprenorphine should factor in crime. Addiction, 96, 1515.CrossRefPubMedGoogle Scholar
  61. [61]
    Sindelar, J.L. (2001). Opioid maintenance: the politics matter. Addiction, 96, 1517–1518.PubMedGoogle Scholar
  62. [62]
    Wall, M.J. and H.A. Pollack (2002). Cost-utility of selective buprenorphine substitution for methadone maintenance in preventing HIV transmission. Value in Health, 5, 260.Google Scholar
  63. [63]
    Schottenfeld, R.S., J.R. Pakes, A. Oliveto, D. Ziedonis, and T.R. Kosten (1997). Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry, 54, 713–720.PubMedGoogle Scholar
  64. [64]
    U.S. Food and Drug Administration (2002). Subutex and Suboxone approved to treat opiate dependence, http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01165.html, Accessed April 25, 2002.
  65. [65]
    O’Connor, P.G. and T.R. Kosten (1998). Rapid and ultrarapid opioid detoxification techniques. Journal of the American Medical Association, 279, 229–234.PubMedCrossRefGoogle Scholar
  66. [66]
    Hamilton, R.J., et al. (2002). Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Academic Emergency Medicine, 9, 63–68.CrossRefPubMedGoogle Scholar
  67. [67]
    Kutz, I. and V. Reznik (2001). Rapid heroin detoxification using a single high dose of buprenorphine. Journal of Psychoactive Drugs, 33, 191–193.PubMedGoogle Scholar
  68. [68]
    Thirion, X., et al. (2002). Buprenorphine prescription by general practitioners in a French region. Drug and Alcohol Dependence, 65, 197–204.CrossRefPubMedGoogle Scholar
  69. [69]
    Strang, J., J. Sheridan, and N. Barber (1996). Prescribing injectable and oral methadone to opiate addicts: results from the 1995 national postal survey of community pharmacies in England and Wales. British Medical Journal, 313, 270–272.PubMedGoogle Scholar
  70. [70]
    Wodak, A. (2002). Methadone and heroin prescription: babies and bath water. Substance Use and Misuse, 37, 523–531.CrossRefPubMedGoogle Scholar
  71. [71]
    Wenger, L.D. and M. Rosenbaum (1994). Drug treatment on demand-not. Journal of Psychoactive Drugs, 26, 1–11.PubMedGoogle Scholar
  72. [72]
    Simeone, R.S. (1993). A note on waiting lists and demand estimation. International Journal of the Addictions, 28, 1033–8.PubMedGoogle Scholar
  73. [73]
    Kaplan, E.H. and M. Johri (2000). Treatment on demand: An operational model. Health Care Management Science, 3, 171–183.CrossRefPubMedGoogle Scholar
  74. [74]
    Guydish, J., et al. (2000). Drug abuse treatment on demand in San Francisco: preliminary findings. Journal of Psychoactive Drugs, 32, 363–370.PubMedGoogle Scholar
  75. [75]
    Bonds, D.E. and K.A. Freedberg (2001). Combining utility measurements-Exploring different approaches. Disease Management and Health Outcomes, 9, 507–516.CrossRefGoogle Scholar
  76. [76]
    Darrow, W.W., et al. (1999). Using knowledge of social networks to prevent human immunodeficiency virus infections: The Colorado Springs study. Sociological Focus, 32, 143–158.Google Scholar
  77. [77]
    Klovdahl, A.S., et al. (1994). Social networks and infectious disease: The Colorado Springs study. Social Science and Medicine, 38, 79–88.PubMedCrossRefGoogle Scholar
  78. [78]
    Neaigus, A., et al. (1996). High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors. Journal of Acquired Immune Deficiency Syndromes, 11, 499–509.Google Scholar
  79. [79]
    Kaplan, E.H., P.C. Crampton, and A.D. Paltiel (1989). Nonrandom mixing models of HIV transmission. In Mathematical and Statistical Approaches to AIDS Epidemiology, C. Castillo-Chavez, Ed., Springer-Verlag, Berlin.Google Scholar
  80. [80]
    Kaplan, E.H. and Y.S. Lee (1990). How bad can it get? Bounding worst case endemic heterogeneous mixing models of HIV/AIDS. Mathematical Biosciences, 99, 157–180.CrossRefPubMedMathSciNetGoogle Scholar
  81. [81]
    Kaplan, E.H. (1992). Asymptotic worst-case mixing in simple demographic models of HIV/AIDS. Mathematical Biosciences, 108, 141–156.CrossRefzbMATHPubMedGoogle Scholar
  82. [82]
    Pastor-Satorras, R. and A. Vespignani (2001). Epidemic spreading in scale-free networks. Physical Review Letters, 86, 3200–3203.CrossRefADSPubMedGoogle Scholar
  83. [83]
    Watts, D.J. (1999). Small Worlds: The Dynamics of Networks Between Order and Randomness. Princeton University Press, Princeton, NJ.Google Scholar
  84. [84]
    Zaric, G.S. (2002). Random vs. nonrandom mixing in network epidemic models. Health Care Management Science, 5, 147–155.CrossRefPubMedGoogle Scholar
  85. [85]
    Koblin, B.A., J. McCusker, B.F. Lewis, and J.L. Sullivan (1990). Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. American Journal of Epidemiology, 132, 837–846.PubMedGoogle Scholar
  86. [86]
    Meandzija, B., P.G. O’Connor, B. Fitzgerald, B.J. Rounsaville, and T.R. Kosten (1994). HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug and Alcohol Dependence, 36, 109–113.CrossRefPubMedGoogle Scholar
  87. [87]
    Laumann, E.O., J.H. Gagnon, R.T. Michael, and S. Michaels (1994). The Social Organization of Sexuality: Sexual Practices in the United States. University of Chicago Press, Chicago, IL.Google Scholar
  88. [88]
    Kuntz, K.M. and S.J. Goldie (2002). Assessing the sensitivity of decision-analytic results to unobserved markers of risk: Defining the effects of heterogeneity bias. Medical Decision Making, 22, 218–227.CrossRefPubMedGoogle Scholar
  89. [89]
    Zaric, G.S. (2002). The danger of ignoring population heterogeneity when Markov models are used in cost effectiveness analysis. Value in Health, 5, 125.Google Scholar
  90. [90]
    Pollack, H.A. (2001). Ignoring ‘downstream infection’ in the evaluation of harm reduction interventions for injection drug users. European Journal of Epidemiology, 17, 391–395.CrossRefPubMedGoogle Scholar
  91. [91]
    Weber, J.C. and J. Kopferschmitt (1998). Substitution treatments for drug abusers. Presse Medicale, 27, 2088–2099.Google Scholar
  92. [92]
    Caulkins, J.P. and S.L. Satel (1999). Methadone patients should not be allowed to persist in cocaine use. Federation of American Scientists’ Drug Policy Analysis Bulletin, 6, 1–4.Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Gregory S. Zaric
    • 1
  1. 1.Richard Ivey School of BusinessUniversity of Western OntarioLondonCanada

Personalised recommendations